ALK
Anaplastic Lymphoma Kinase. Fusion driver in ~5% of NSCLC; targeted by alectinib, lorlatinib, brigatinib, ceritinib.
No Treatments found for this biomarker.
Anaplastic Lymphoma Kinase. Fusion driver in ~5% of NSCLC; targeted by alectinib, lorlatinib, brigatinib, ceritinib.
No Treatments found for this biomarker.